Silencing Mutated β-Catenin Inhibits Cell Proliferation and Stimulates Apoptosis in the Adrenocortical Cancer Cell Line H295R

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gaujoux, Sébastien ^a,b,c   Hantel, Constanze ^d   Launay, Pierre ^a,b   Bonnet, Stéphane ^a,b,c   Perlemoine, Karine ^a,b   Lefèvre, Lucile ^a,b   Guillaud Bataille, Marine ^a,b   Beuschlein, Felix ^d   Tissier, Frédérique ^a,b,c,e   Bertherat, Jérôme ^a,b,c,e   Rizk Rabin, Marthe ^a,b   Ragazzon, Bruno ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c Department of Digestive and Endocrine Surgery ^*  (France)

^d UNIVERSITY OF MUNICH   (Germany)

^e INSTITUT NATIONAL DU CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DOXYCYCLINE; LUCIFERASE; SHORT HAIRPIN RNA;

ADRENAL CORTEX CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN H295R; CONTROLLED STUDY; CTNNB1 GENE; ENZYME ACTIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANIMALS; APOPTOSIS; BETA CATENIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE SILENCING; HUMANS; MICE; MUTATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; WNT PROTEINS;

EID: 84873577222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055743     Document Type: Article

References (20)

1. Abiven G, Coste J, Groussin L, Anract P, Tissier F, et al. (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91: 2650-2655.
2. Libe R, Fratticci A, Bertherat J, (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14: 13-28.
3. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, et al. (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113: 3130-3136.
4. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, et al. (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115: 243-250.
5. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, et al. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65: 7622-7627.
6. Gaujoux S, Tissier F, Groussin L, Libe R, Ragazzon B, et al. (2008) Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 93: 4135-4140.
7. Tadjine M, Lampron A, Ouadi L, Bourdeau I, (2008) Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 68: 264-270.
8. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, et al. (2011) {beta}-catenin activation is associated with specific clinical and pathological characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res.
9. Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, et al. (2011) Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and-nonsecreting tumors. J Clin Endocrinol Metab 96: E419-426.
10. Kim A, Giordano TJ, Kuick R, Serecky K, Hammer GD, (2009) Wnt/betacatenin signaling in adrenocortical stem/progenitor cells: implications for adrenocortical carcinoma. Ann Endocrinol (Paris) 70: 156.
11. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, et al. (2010) Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 19: 1561-1576.
12. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, et al. (2010) Transcriptome Analysis Reveals that p53 and {beta}-Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers. Cancer Res 70: 8276-8281.
13. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, et al. (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol 21: 2968-2987.
14. Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, et al. (2009) Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res 69: 7278-7284.
15. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, et al. (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4: 609-615.
16. Groussin L, Massias JF, Bertagna X, Bertherat J, (2000) Loss of expression of the ubiquitous transcription factor cAMP response element-binding protein (CREB) and compensatory overexpression of the activator CREMtau in the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 85: 345-354.
17. Rizk-Rabin M, Assie G, Rene-Corail F, Perlemoine K, Hamzaoui H, et al. (2008) Differential expression of parathyroid hormone-related protein in adrenocortical tumors: autocrine/paracrine effects on the growth and signaling pathways in H295R cells. Cancer Epidemiol Biomarkers Prev 17: 2275-2285.
18. Hantel C, Lewrick F, Schneider S, Zwermann O, Perren A, et al. (2010) Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency. J Clin Endocrinol Metab 95: 943-952.
19. Behrens J, Lustig B, (2004) The Wnt connection to tumorigenesis. Int J Dev Biol 48: 477-487.
20. Doghman M, Cazareth J, Lalli E, (2008) The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 93: 3222-3225.